FDA inspection
Glaxo Smith Kline: FDA inspection ending Feb 25, 2004
FDA inspection 314644 · Voluntary Action Indicated (VAI) · Parsippany, NJ
Key facts
| Inspection ID | 314644 |
|---|---|
| Firm | Glaxo Smith Kline |
| FEI number | 3004006471 |
| Address | 1500 Littleton Rd |
| City | Parsippany |
| State | NJ |
| ZIP | 07054-3804 |
| Fiscal year | 2004 |
| Inspection end date | Feb 25, 2004 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Post Mrkt Surv & Epid: Human Drugs |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data